Sell High Purity 99% Pharmaceutical Grade Yk11 Sarm 431579-34-9

Model NO.: CAS 431579-34-9
CAS: 431579-34-9
Formula: C152h252n44o42
Molecular Weight: 3367.2
MOQ: 1g
Delivery: 8hrs After Payment
Arrive: 4-6 Days
Appearance: White Powder
Trademark: Yijing
Transport Package: Disguise
Specification: USP/EP/BP
Origin: China
HS Code: 3402
Model NO.: CAS 431579-34-9
CAS: 431579-34-9
Formula: C152h252n44o42
Molecular Weight: 3367.2
MOQ: 1g
Delivery: 8hrs After Payment
Arrive: 4-6 Days
Appearance: White Powder
Trademark: Yijing
Transport Package: Disguise
Specification: USP/EP/BP
Origin: China
HS Code: 3402
Sell High Purity 99% Pharmaceutical Grade Yk11 Sarm 431579-34-9

Sell High Purity 99% Pharmaceutical Grade Yk11 Sarm 431579-34-9

What is YK11?
 
(17α,20E)-17,20-[(1-methoxyethylidene)bis-(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), which the myogenic differentiation of C2C12 myoblast cells is induced by the novel androgen receptor (AR) partial agonist. as well as by dihydrotestosterone (DHT).
YK11 is a selective androgen receptor modulator (SARM), which activates AR without the N/C interaction. In this study, we further investigated the mechanism by which YK11 induces myogenic differentiation of C2C12 cells. The induction of key myogenic regulatory factors (MRFs), such as myogenic differentiation factor (MyoD), myogenic factor 5 (Myf5) and myogenin, was more significant in the presence of YK11 than in the presence of DHT. YK11 treatment of C2C12 cells, but not DHT, induced the expression of follistatin (Fst), and the YK11-mediated myogenic differentiation was reversed by anti-Fst antibody.
 
Myogenic differentiation is in reference to the products ability to block myostatin. Myostatin inhibition has been a really popular movement since the ban of most prohormones as it looks to be a relatively unexplored area for muscle growth and fat loss. There are currently a lot of claims about mystatin inhibition, but not so much factual data on these products. YK11 will have similar affects to DHT (possibly more potent) without the negatives of DHT. What this means is that the product will most likely be suppressive and require a post cycle, but not cycle support. It also won't have androgenic side affects like hair loss, acne, etc. The increase in follistatin caused by YK11 will act as an antagonist to mystatin (it will block myostatin) as well as the anabolic growth properties of YK11.
 
 
How it works?
 
Animal Research:
In direct comparison to to LGD-4033 as the reference for assay upon animal models of anabolism and androgenicity, YK-11 demonstrated higher efficacy withing anabolic parameters and lesser androgenicity at equivalent dosages.

It induces muscle cells to make more follistatin which is a strong myostatin inhibitor. Myostatin (also known as growth differentiation factor 8, is a myokine (protein) produced by muscle cells that acts on muscle cells to inhibit myogenesis. Myogenesis is muscle cell growth and differentiation. Research through the years show that when you block myostatin, it allows for significantly more muscle mass. So in research myostatin inhibitors are researched to find cures for muscle diseases.

We expect YK11 to be more potent than SARM LGD in terms of overall growth and feel. At this time, we expect this to be the strongest SARM on the market at a regular dosing. While suppression can occur, we expect this product to have low androgenic properties and can be used by both men and women. From our experience with SARMs, we find there are less losses of on-cycle results than pro-hormones, although typically not as potent. We do expect this product to have similar results as a moderately dosed Halodrol, without the alpha-male/androgenic feelings while on it.
 
 
Dosages and Suggestion
 
Recommended maximum dose YK11 is require dosages of 2.0-5.0mg b.i.d. in males and 0.5mg-2mg b.i.d. in females to achieve optimal effects in humans for the noted indications.

 

SARMS We offer:

 

AICAR
2627-69-2 acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown
MK2866 841205-47-8 medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy.
MK-677 15972-10-0 A hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly
LGD-4033 1165910-22-4 pharmacological profile similar to that of enobosarm, Ostarine,MK-2866
GW501516 317318-70-0 For obesity, diabetes, dyslipidemia and cardiovascular disease
Andarine(S4) 401900-40-0 partial agonist, intended mainly for treatment of benign prostatic hypertrophy
SR9009 1379686-30-2 under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice
SR9011 1379686-30-2 For obesity, diabetes, dyslipidemia and cardiovascular disease
RAD140 1182367-47-0 New generation for gaining mass and cutting edges
YK11
366508-78-3
431579-34-9

a SARM and myostatin inhibitor in one
GHRP-2 158861-67-7 Hormone Releasing Peptide-2
GHRP-6 87616-84-0 Hormone Releasing Peptide-6
TB500 107761-42-2 Thymosin beta 4
SM130,686 / /

Polypeptide Series
Product Name Specification
MGF 2mg/vial
PEG MGF 2mg/vial
CJC-1295 with DAC 2mg/vial
CJC-1295 without DAC 2mg/vial
PT-141 10mg/vial
MT-1 10mg/vial
MT-2 10mg/vial
GHRP-2 5mg/vial
GHRP-2 10mg/vial
GHRP-6 5mg/vial
GHRP-6 10mg/vial
Ipamorelin 2mg/vial
Hexarelin 2mg/vial
Sermorelin 2mg/vial
Oxytocin 2mg/vial
TB500 2mg/vial
pentadecapeptide BPC 157 2mg/vial
176-191 2mg/vial
Triptorelin 2mg/vial
Tesamorelin 2mg/vial
Gonadorelin 2mg/vial
Gonadorelin 10mg/vial
DSIP 2mg/vial
Selank 5mg/vial
 
How to proceed the order:
1) Orders : For mutiple items and large volume clients, substantial discounts can be arranged onan individual basis.
2)Payment options:Western Union, MoneyGram, T/T
3) Shipping method : Super discreet packaging, to ensure safe delivery
4) Delivery area : Kazakhstan ,Poland,Hungary ,Paraguay ,Uruguay,Brazil, Russia, Portugal,Latvia, Switzerland, Iceland,Ukraine, Germany, France, Netherlands, Belgium,Peru, Sweden, NewZealand, the Czech Republic, Lithuania,Ireland, Tunisia, Mexico, Greece, Puerto Rico,Serbia,Finland ,Italy , Estonia ,Thailand, Israel ,US, UK, Canada, Australia



2018 exhibition API and CHPI:

Sell High Purity 99% Pharmaceutical Grade Yk11 Sarm 431579-34-9
 
Warehouse:
 
Sell High Purity 99% Pharmaceutical Grade Yk11 Sarm 431579-34-9
 
Transportion:
 
Sell High Purity 99% Pharmaceutical Grade Yk11 Sarm 431579-34-9
 
Factory and office:
 
Sell High Purity 99% Pharmaceutical Grade Yk11 Sarm 431579-34-9 Sell High Purity 99% Pharmaceutical Grade Yk11 Sarm 431579-34-9

Sell High Purity 99% Pharmaceutical Grade Yk11 Sarm 431579-34-9

What is YK11?
 
(17α,20E)-17,20-[(1-methoxyethylidene)bis-(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), which the myogenic differentiation of C2C12 myoblast cells is induced by the novel androgen receptor (AR) partial agonist. as well as by dihydrotestosterone (DHT).
YK11 is a selective androgen receptor modulator (SARM), which activates AR without the N/C interaction. In this study, we further investigated the mechanism by which YK11 induces myogenic differentiation of C2C12 cells. The induction of key myogenic regulatory factors (MRFs), such as myogenic differentiation factor (MyoD), myogenic factor 5 (Myf5) and myogenin, was more significant in the presence of YK11 than in the presence of DHT. YK11 treatment of C2C12 cells, but not DHT, induced the expression of follistatin (Fst), and the YK11-mediated myogenic differentiation was reversed by anti-Fst antibody.
 
Myogenic differentiation is in reference to the products ability to block myostatin. Myostatin inhibition has been a really popular movement since the ban of most prohormones as it looks to be a relatively unexplored area for muscle growth and fat loss. There are currently a lot of claims about mystatin inhibition, but not so much factual data on these products. YK11 will have similar affects to DHT (possibly more potent) without the negatives of DHT. What this means is that the product will most likely be suppressive and require a post cycle, but not cycle support. It also won't have androgenic side affects like hair loss, acne, etc. The increase in follistatin caused by YK11 will act as an antagonist to mystatin (it will block myostatin) as well as the anabolic growth properties of YK11.
 
 
How it works?
 
Animal Research:
In direct comparison to to LGD-4033 as the reference for assay upon animal models of anabolism and androgenicity, YK-11 demonstrated higher efficacy withing anabolic parameters and lesser androgenicity at equivalent dosages.

It induces muscle cells to make more follistatin which is a strong myostatin inhibitor. Myostatin (also known as growth differentiation factor 8, is a myokine (protein) produced by muscle cells that acts on muscle cells to inhibit myogenesis. Myogenesis is muscle cell growth and differentiation. Research through the years show that when you block myostatin, it allows for significantly more muscle mass. So in research myostatin inhibitors are researched to find cures for muscle diseases.

We expect YK11 to be more potent than SARM LGD in terms of overall growth and feel. At this time, we expect this to be the strongest SARM on the market at a regular dosing. While suppression can occur, we expect this product to have low androgenic properties and can be used by both men and women. From our experience with SARMs, we find there are less losses of on-cycle results than pro-hormones, although typically not as potent. We do expect this product to have similar results as a moderately dosed Halodrol, without the alpha-male/androgenic feelings while on it.
 
 
Dosages and Suggestion
 
Recommended maximum dose YK11 is require dosages of 2.0-5.0mg b.i.d. in males and 0.5mg-2mg b.i.d. in females to achieve optimal effects in humans for the noted indications.

 

SARMS We offer:

 

AICAR
2627-69-2 acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown
MK2866 841205-47-8 medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy.
MK-677 15972-10-0 A hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly
LGD-4033 1165910-22-4 pharmacological profile similar to that of enobosarm, Ostarine,MK-2866
GW501516 317318-70-0 For obesity, diabetes, dyslipidemia and cardiovascular disease
Andarine(S4) 401900-40-0 partial agonist, intended mainly for treatment of benign prostatic hypertrophy
SR9009 1379686-30-2 under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice
SR9011 1379686-30-2 For obesity, diabetes, dyslipidemia and cardiovascular disease
RAD140 1182367-47-0 New generation for gaining mass and cutting edges
YK11
366508-78-3
431579-34-9

a SARM and myostatin inhibitor in one
GHRP-2 158861-67-7 Hormone Releasing Peptide-2
GHRP-6 87616-84-0 Hormone Releasing Peptide-6
TB500 107761-42-2 Thymosin beta 4
SM130,686 / /

Polypeptide Series
Product Name Specification
MGF 2mg/vial
PEG MGF 2mg/vial
CJC-1295 with DAC 2mg/vial
CJC-1295 without DAC 2mg/vial
PT-141 10mg/vial
MT-1 10mg/vial
MT-2 10mg/vial
GHRP-2 5mg/vial
GHRP-2 10mg/vial
GHRP-6 5mg/vial
GHRP-6 10mg/vial
Ipamorelin 2mg/vial
Hexarelin 2mg/vial
Sermorelin 2mg/vial
Oxytocin 2mg/vial
TB500 2mg/vial
pentadecapeptide BPC 157 2mg/vial
176-191 2mg/vial
Triptorelin 2mg/vial
Tesamorelin 2mg/vial
Gonadorelin 2mg/vial
Gonadorelin 10mg/vial
DSIP 2mg/vial
Selank 5mg/vial
 
How to proceed the order:
1) Orders : For mutiple items and large volume clients, substantial discounts can be arranged onan individual basis.
2)Payment options:Western Union, MoneyGram, T/T
3) Shipping method : Super discreet packaging, to ensure safe delivery
4) Delivery area : Kazakhstan ,Poland,Hungary ,Paraguay ,Uruguay,Brazil, Russia, Portugal,Latvia, Switzerland, Iceland,Ukraine, Germany, France, Netherlands, Belgium,Peru, Sweden, NewZealand, the Czech Republic, Lithuania,Ireland, Tunisia, Mexico, Greece, Puerto Rico,Serbia,Finland ,Italy , Estonia ,Thailand, Israel ,US, UK, Canada, Australia



2018 exhibition API and CHPI:

Sell High Purity 99% Pharmaceutical Grade Yk11 Sarm 431579-34-9
 
Warehouse:
 
Sell High Purity 99% Pharmaceutical Grade Yk11 Sarm 431579-34-9
 
Transportion:
 
Sell High Purity 99% Pharmaceutical Grade Yk11 Sarm 431579-34-9
 
Factory and office:
 
Sell High Purity 99% Pharmaceutical Grade Yk11 Sarm 431579-34-9

Endo Files

Endo Files,Dental Endo Files,Dental Rotary Files

Dental Equipment Co., Ltd. , http://www.sofine-dental.com